SE9602442D0 - Administration of pharmaceuticals - Google Patents

Administration of pharmaceuticals

Info

Publication number
SE9602442D0
SE9602442D0 SE9602442A SE9602442A SE9602442D0 SE 9602442 D0 SE9602442 D0 SE 9602442D0 SE 9602442 A SE9602442 A SE 9602442A SE 9602442 A SE9602442 A SE 9602442A SE 9602442 D0 SE9602442 D0 SE 9602442D0
Authority
SE
Sweden
Prior art keywords
extended
atpase
pharmaceuticals
administration
profile
Prior art date
Application number
SE9602442A
Other languages
English (en)
Swedish (sv)
Inventor
Christer Cederberg
George Sachs
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9602442A priority Critical patent/SE9602442D0/xx
Publication of SE9602442D0 publication Critical patent/SE9602442D0/xx
Priority to PT97930933T priority patent/PT921787E/pt
Priority to EP97930933A priority patent/EP0921787B1/en
Priority to SK1655-98A priority patent/SK284204B6/sk
Priority to HU9901794A priority patent/HUP9901794A3/hu
Priority to AU34690/97A priority patent/AU726859B2/en
Priority to UA99010150A priority patent/UA64715C2/uk
Priority to PL97330910A priority patent/PL189716B1/pl
Priority to SI9730615T priority patent/SI0921787T1/xx
Priority to DK97930933T priority patent/DK0921787T3/da
Priority to CA002257405A priority patent/CA2257405A1/en
Priority to CZ0420398A priority patent/CZ298213B6/cs
Priority to CNB971955387A priority patent/CN1178648C/zh
Priority to DE69725860T priority patent/DE69725860T2/de
Priority to AT97930933T priority patent/ATE252885T1/de
Priority to BR9709838A priority patent/BR9709838A/pt
Priority to IL12754297A priority patent/IL127542A0/xx
Priority to NZ332990A priority patent/NZ332990A/xx
Priority to ES97930933T priority patent/ES2208921T3/es
Priority to PCT/SE1997/001098 priority patent/WO1997048380A1/en
Priority to JP10502822A priority patent/JP2000512993A/ja
Priority to TR1998/02647T priority patent/TR199802647T2/xx
Priority to US08/945,425 priority patent/US20010008900A1/en
Priority to EE9800435A priority patent/EE04606B1/xx
Priority to RU99101081/14A priority patent/RU2203662C2/ru
Priority to YUP-566/98A priority patent/RS49590B/sr
Priority to IL127542A priority patent/IL127542A/en
Priority to IS4923A priority patent/IS2216B/is
Priority to NO19985964A priority patent/NO323295B1/no
Priority to HK99103406A priority patent/HK1018590A1/xx
Priority to US10/871,506 priority patent/US20050113418A1/en
Priority to US11/544,956 priority patent/US20070276007A1/en
Priority to US12/242,006 priority patent/US20090036494A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9602442A 1996-06-20 1996-06-20 Administration of pharmaceuticals SE9602442D0 (sv)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals
BR9709838A BR9709838A (pt) 1996-06-20 1997-06-18 Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
AT97930933T ATE252885T1 (de) 1996-06-20 1997-06-18 Plan zur verabreichung von h+, k+-atpase inhibitoren
EE9800435A EE04606B1 (et) 1996-06-20 1997-06-18 H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
SK1655-98A SK284204B6 (sk) 1996-06-20 1997-06-18 Použitie inhibítora H+, K+-ATPázy
HU9901794A HUP9901794A3 (en) 1996-06-20 1997-06-18 Administration regimen of h+,k+-atpase inhibitors
AU34690/97A AU726859B2 (en) 1996-06-20 1997-06-18 Administration regimen of H+, K+-ATPase inhibitors
UA99010150A UA64715C2 (en) 1996-06-20 1997-06-18 Pharmaceutical composition with extended release of h+, k+-atpase inhibitor (variants) and method for enhancing inhibition of acid secretion in stomach
NZ332990A NZ332990A (en) 1996-06-20 1997-06-18 oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile
SI9730615T SI0921787T1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+,K+-ATPase INHIBITORS
DK97930933T DK0921787T3 (da) 1996-06-20 1997-06-18 Indgivelsesdosering af H+, K+ -ATPase-inhibitorer
CA002257405A CA2257405A1 (en) 1996-06-20 1997-06-18 Administration regimen of h+, k+-atpase inhibitors
CZ0420398A CZ298213B6 (cs) 1996-06-20 1997-06-18 Lécivo pro zlepsení inhibice sekrece zaludecní kyseliny
CNB971955387A CN1178648C (zh) 1996-06-20 1997-06-18 H+ 、k+ －atp酶抑制剂在制备用于增强抑制胃酸分泌的口服药物中的用途
DE69725860T DE69725860T2 (de) 1996-06-20 1997-06-18 PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
PT97930933T PT921787E (pt) 1996-06-20 1997-06-18 Regime de administracao de inibidores de atpase de h',k'
IL12754297A IL127542A0 (en) 1996-06-20 1997-06-18 Administration regimen of H+ K+ -ATPase inhibitors
RU99101081/14A RU2203662C2 (ru) 1996-06-20 1997-06-18 РЕЖИМ ВВЕДЕНИЯ ИНГИБИТОРОВ Н+, К+-АТФазы
PL97330910A PL189716B1 (pl) 1996-06-20 1997-06-18 Zastosowanie inhibitora H+, K+-ATPazy
ES97930933T ES2208921T3 (es) 1996-06-20 1997-06-18 Regimen de administracion de los inhibidores de la h+,k+-atpasa.
PCT/SE1997/001098 WO1997048380A1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+, K+-ATPase INHIBITORS
JP10502822A JP2000512993A (ja) 1996-06-20 1997-06-18 Ｈ▲上＋▼，ｋ▲上＋▼−ａｔｐアーゼ阻害剤の投与計画
TR1998/02647T TR199802647T2 (xx) 1996-06-20 1997-06-18 H+, K+-ATPaz inhibit�rlerinin administrasyon rejimi.
US08/945,425 US20010008900A1 (en) 1996-06-20 1997-06-18 Administration of pharmaceuticals
EP97930933A EP0921787B1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+,K+-ATPase INHIBITORS
YUP-566/98A RS49590B (sr) 1996-06-20 1998-12-09 Upotreba inhibitora h+,k+-atpaze za proizvodnju novih farmaceutskih preparata
IL127542A IL127542A (en) 1996-06-20 1998-12-13 H+, K+-ATPase INHIBITORS FOR USE IN IMPROVED INHIBITION OF GASTRIC ACID SECRETION
IS4923A IS2216B (is) 1996-06-20 1998-12-15 Meðferðaráform við inngjöf á H+,K+ -ATPasa-hemla
NO19985964A NO323295B1 (no) 1996-06-20 1998-12-18 Anvendelse av H+,K+-ATPase-inhibitorer for fremstilling av oralt administrerbare medikamenter for inhibering av magesyresekresjon
HK99103406A HK1018590A1 (en) 1996-06-20 1999-08-06 Administration regimen of h+, k+-atpase inhibitors
US10/871,506 US20050113418A1 (en) 1996-06-20 2004-06-18 Administration of pharmaceuticals
US11/544,956 US20070276007A1 (en) 1996-06-20 2006-10-05 Administration of pharmaceuticals
US12/242,006 US20090036494A1 (en) 1996-06-20 2008-09-30 Administration of Pharmaceuticals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals

Publications (1)

Publication Number Publication Date
SE9602442D0 true SE9602442D0 (sv) 1996-06-20

Family

ID=20403092

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals

Country Status (28)

Country Link
US (4) US20010008900A1 (xx)
EP (1) EP0921787B1 (xx)
JP (1) JP2000512993A (xx)
CN (1) CN1178648C (xx)
AT (1) ATE252885T1 (xx)
AU (1) AU726859B2 (xx)
BR (1) BR9709838A (xx)
CA (1) CA2257405A1 (xx)
CZ (1) CZ298213B6 (xx)
DE (1) DE69725860T2 (xx)
DK (1) DK0921787T3 (xx)
EE (1) EE04606B1 (xx)
ES (1) ES2208921T3 (xx)
HK (1) HK1018590A1 (xx)
HU (1) HUP9901794A3 (xx)
IL (2) IL127542A0 (xx)
IS (1) IS2216B (xx)
NO (1) NO323295B1 (xx)
NZ (1) NZ332990A (xx)
PL (1) PL189716B1 (xx)
PT (1) PT921787E (xx)
RS (1) RS49590B (xx)
RU (1) RU2203662C2 (xx)
SE (1) SE9602442D0 (xx)
SK (1) SK284204B6 (xx)
TR (1) TR199802647T2 (xx)
UA (1) UA64715C2 (xx)
WO (1) WO1997048380A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
WO1999055157A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. R-rabeprazole compositions and methods
CA2330324A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. S-rabeprazole compositions and methods
JP4346243B2 (ja) 1998-08-10 2009-10-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロトン・ポンプ・インヒビターのプロドラッグ
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
DK1105105T3 (da) 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
JPH08509736A (ja) * 1993-04-27 1996-10-15 セプラコー，インコーポレイテッド 光学的に純粋な（−）パントプラゾールを用いる胃の疾患治療の方法と組成
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DE29522419U1 (de) * 1994-07-08 2003-07-03 AstraZeneca AB, Södertälje Tablettierte Mehrfacheinheits-Dosisform
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Also Published As

Publication number Publication date
SK165598A3 (en) 1999-08-06
ES2208921T3 (es) 2004-06-16
US20070276007A1 (en) 2007-11-29
HUP9901794A2 (hu) 2000-04-28
CN1178648C (zh) 2004-12-08
EE9800435A (et) 1999-06-15
EP0921787B1 (en) 2003-10-29
DK0921787T3 (da) 2004-02-23
SK284204B6 (sk) 2004-10-05
IL127542A (en) 2006-08-01
RU2203662C2 (ru) 2003-05-10
PT921787E (pt) 2004-03-31
PL189716B1 (pl) 2005-09-30
WO1997048380A1 (en) 1997-12-24
EP0921787A1 (en) 1999-06-16
IS4923A (is) 1998-12-15
TR199802647T2 (xx) 1999-03-22
PL330910A1 (en) 1999-06-07
NO323295B1 (no) 2007-03-05
EE04606B1 (et) 2006-04-17
DE69725860D1 (de) 2003-12-04
RS49590B (sr) 2007-06-04
US20050113418A1 (en) 2005-05-26
CA2257405A1 (en) 1997-12-24
CN1222074A (zh) 1999-07-07
AU726859B2 (en) 2000-11-23
IL127542A0 (en) 1999-10-28
NZ332990A (en) 2000-07-28
CZ420398A3 (cs) 2000-02-16
US20010008900A1 (en) 2001-07-19
YU56698A (sh) 2004-12-31
HUP9901794A3 (en) 2002-11-28
IS2216B (is) 2007-03-15
CZ298213B6 (cs) 2007-07-25
NO985964D0 (no) 1998-12-18
NO985964L (no) 1999-02-22
UA64715C2 (en) 2004-03-15
HK1018590A1 (en) 1999-12-30
AU3469097A (en) 1998-01-07
JP2000512993A (ja) 2000-10-03
DE69725860T2 (de) 2004-09-09
ATE252885T1 (de) 2003-11-15
US20090036494A1 (en) 2009-02-05
BR9709838A (pt) 1999-08-10

Similar Documents

Publication Publication Date Title
SE9602442D0 (sv) Administration of pharmaceuticals
SE9704870D0 (sv) New pharmaceutical formulation I
IT1312377B1 (it) Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
ATE165971T1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
AP9701041A0 (en) Pyridylpyrrole compounds.
DK0929565T3 (da) Nitratestere af corticoidforbindelser og farmaceutiske anvendelser deraf
DE60019334D1 (de) Antivirale arznei
DE69033970D1 (de) Huperzin a analoge verbindungen
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
GEP20063719B (en) Prevention of Migraine Recurrence
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
WO1998038994A3 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
IT1244373B (it) Composizioni farmaceutiche per uso orale contenenti eparina a basso peso molecolare, loro preparazione ed uso
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
PT777471E (pt) Metodo de inibicao da biosintese de leucotrieno
MX9804798A (es) Nuevos compuestos con efecto analgesico.
MX9804797A (es) Nuevos compuestos con efecto analgesico.
DK0615446T3 (da) Retard-lægemiddel indeholdende et dihydropyridinderivat i nanosolform og fremstilling heraf